2019 to 2020 Saw 1.5-Year Decline in U.S. Life Expectancy at Birth
Mortality due to COVID-19 had biggest effect on decline in life expectancy for both men and women, all races examined
Multitarget Fecal Immunochemical Test Ups Diagnostic Accuracy
Cross-validated sensitivity improved with multitarget FIT compared with standard FIT test for advanced neoplasia and advanced adenoma
Rates of Adverse Events Lower With Apixaban for A-Fib in Older Adults
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
Non-Antimicrobial Drugs Tied to Drug-Resistant Bacterial Infection
Proton pump inhibitors, beta-blockers, antimetabolites linked to infection with antibiotic-resistant bacteria
ASH Suggests Not Using Outpatient Thromboprophylaxis for COVID-19
For discharged patients without suspected or confirmed VTE or other indication for anticoagulation, panel suggests not using anticoagulants
Adding Ipilimumab to Nivolumab No Better in Pretreated Squamous NSCLC
No difference in overall survival seen with nivolumab plus ipilimumab, nivolumab alone for advanced, chemotherapy-pretreated disease
No Benefit Seen From Adjuvant Celecoxib in ERBB2-Negative Breast Cancer
Disease-free survival did not improve with two years of celecoxib versus placebo in ERBB2-negative breast cancer
CDC Advisers to Discuss Third COVID-19 Vaccine Dose for Immunocompromised
Booster shots have become a hot topic since Pfizer-BioNTech said last week it would seek EUA for a third shot of its two-dose vaccine
Ruxolitinib Best for Glucocorticoid-Refractory, -Dependent GVHD
Overall response, failure-free survival, symptom response significantly greater with ruxolitinib versus control therapy
Impact of Pandemic Projected for U.S. Breast Cancer Mortality
Cumulative increase of 0.52 percent expected in breast cancer deaths by 2030 due to disruptions during the first six months of the pandemic
